Full-Time
Senior Medical Writer
Clinical Studies
AXON
5,001-10,000 employees
Public-safety technology provider with TASER
Compensation Overview
CA$115k - CA$130k/yr
Toronto, ON, Canada
Hybrid
Three days on-site per week required.
Master's, PharmD, PhD, MD
 Content & Writing (1) |
|---|
Get referred to AXON
See people who can refer or advise you
- An advanced degree in life sciences, pharmacy, medicine, biomedical sciences, or a related discipline, such as a PhD, PharmD, MSc, MD, or equivalent.
- Five to eight or more years of experience in medical communications, healthcare communications, medical education, the pharmaceutical industry, or a healthcare agency environment.
- Demonstrated experience interpreting clinical research and translating complex scientific information into clear, engaging communications.
- Exceptional writing, editing, and storytelling skills with meticulous attention to scientific accuracy and detail.
- Strong understanding of pharmaceutical industry regulations, medical review processes, and compliance standards.
- Experience managing multiple projects across different therapeutic areas and client accounts.
- Strong client-facing communication and presentation skills.
- Proven ability to mentor and develop junior colleagues.
- Excellent organizational, project management, and prioritization skills.
- Capability to work three days a week in-office.
- Ability to travel as required.
- Openness to learning new artificial intelligence tools, experimenting with innovative ways of working, and using artificial intelligence responsibly and transparently.
- Lead the development of high-quality scientific and medical communications across a variety of healthcare accounts.
- Translate complex clinical data into clear, accurate, and engaging content tailored to diverse audiences.
- Serve as a trusted scientific partner to clients by providing expert editorial guidance and participating in client review meetings.
- Mentor and develop junior medical writers while contributing to a collaborative, high-performing team.
- Partner with multidisciplinary colleagues across AXON and the AVENIR GLOBAL network to deliver integrated healthcare communications solutions.
- Lead the development of scientifically accurate, strategically aligned medical content across a broad range of healthcare communications materials.
- Serve as the day-to-day scientific and editorial contact for assigned clients, confidently presenting recommendations and participating in client review meetings.
- Interpret and communicate complex clinical and scientific data for healthcare professionals, patients, and other stakeholder audiences.
- Monitor therapeutic area developments, clinical research, and regulatory milestones, proactively sharing insights with clients and internal teams.
- Collaborate closely with account teams, strategists, creatives, and project managers to deliver integrated client solutions.
- Build strong relationships with clients, healthcare professionals, key opinion leaders, and external partners.
- Contribute scientific expertise to proposals, project planning, and new business opportunities.
- Ensure all deliverables meet AXON's quality standards and comply with pharmaceutical industry regulations and best practices.
- Manage multiple projects simultaneously while maintaining attention to detail and meeting deadlines.
- Mentor junior writers through coaching, constructive feedback, and scientific knowledge sharing.
- A collaborative mindset and passion for advancing healthcare communications.
- Curiosity, adaptability, and enthusiasm for embracing artificial intelligence and emerging technologies in everyday working practices.
- A growth mindset around artificial intelligence and emerging technologies, including openness to learning new tools and using artificial intelligence responsibly and transparently.
Axon provides public safety technology that combines hardware like TASER smart weapons, body-worn cameras, and in-car video systems with cloud-based software for evidence management and real-time situational awareness. Devices capture footage and data which is stored and analyzed in Axon’s SaaS platform through subscriptions, creating a continuous revenue stream alongside hardware sales. Its approach links physical tools with integrated software and analytics to create a connected ecosystem rather than standalone devices. Axon aims to improve public safety outcomes and accountability by giving agencies efficient, data-driven tools to protect lives.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Scottsdale, Arizona
Founded
1993
Get referred to AXON
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue rose 35% to $904 million, Axon's tenth straight over-30% quarter.
- Annual recurring revenue reached $1.6 billion; net revenue retention hit 126%.
- Axon Body Mini launched in June 2026 across the United States, Canada, Britain, Europe, Australia, and New Zealand.
What critics are saying
- Axon faces consolidated antitrust class actions over VieVu and Taser pricing; damages claims continue.
- Q2 software gross margin fell to 75.1% because memory costs and services mix compressed margins.
- Trading around 200 times earnings, Axon needs flawless execution; any federal procurement slowdown hurts growth.
What makes AXON unique
- Axon locks agencies into hardware, software, and long-term bookings; Q2 bookings hit $15.1 billion.
- AI Era Plan, Records, Fusus, and Axon 911 expanded 70% in Q2 2026.
- Dedrone and TASER 10 broaden Axon beyond cameras into counter-drone and conducted-energy weapons.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Disability Insurance
Life Insurance
Wellness Program
Hybrid Work Options
Paid Vacation
Sabbatical Leave
Dental Insurance
Employee Referral Bonus
Professional Development Budget
Growth & Insights and Company News
6 month growth
↑ 20%1 year growth
↑ 20%2 year growth
↑ 20%Axon Enterprise shares rebounded 9.3% on Friday following a 14.3% drop the previous day, with investors reassessing the company's second-quarter 2026 results. The initial sell-off came despite strong performance — revenue rose 35% year-over-year to $904 million, marking the tenth consecutive quarter of growth above 30%. The market's concern centred on compressed gross margins in the software and services segment, driven by rising memory costs and a higher mix of counter-drone hardware sales. Axon's Dedrone division surpassed $100 million in quarterly revenue, contributing to a 123% jump in Platform Solutions revenue. Management raised full-year revenue growth guidance to 32%–34% whilst maintaining its adjusted EBITDA margin outlook at 25.5%. The company expects near-term margin pressure from component costs and hardware scaling, with software revenue anticipated to follow hardware deployments. The third-quarter results will prove whether this margin squeeze represents temporary growing pains or a more persistent challenge.
Axon Enterprise and Chewy represent contrasting investment opportunities: rapid innovation versus predictable recurring revenue. Axon provides Taser devices, body cameras, and cloud-based software for law enforcement, expanding into fire, EMS, and commercial security markets. In FY 2025, Axon's revenue reached nearly $2.8 billion, up roughly a third year-over-year. Net income was nearly $125 million, down from $377 million in 2024, yielding a 5% net margin. The debt-to-equity ratio stands at roughly 0.6x. Chewy dominates digital pet supply through its Autoship subscription programme. FY 2025 revenue hit $12.6 billion, up 6% year-over-year. Net income reached $222.8 million, producing a 2% net margin. Chewy recently acquired Modern Animal and opened Chewy Vet Care clinics to deepen customer relationships.
Wall Street closed lower on Thursday as investors awaited a permanent settlement of Middle East geopolitical conflicts and digested soft earnings from major companies. The Dow Jones Industrial Average fell 0.9%, or 464 points, to close at 53,885.10, ending a five-day winning streak. The tech-heavy Nasdaq Composite slipped 0.1% to finish at 26,363.44, whilst the S&P 500 declined 0.2% to 7,709.96. Geopolitical tensions heightened after an Iranian parliamentary committee reviewed a bill to bar US and Israeli ships from passing through the Strait of Hormuz. This development pushed crude oil prices higher, with West Texas Intermediate futures settling up 2.8% at $77.29 per barrel. Disappointing earnings weighed on sentiment. Axon Enterprise reported quarterly adjusted earnings of $1.88 per share, missing estimates, whilst Honeywell Aerospace's adjusted earnings of $1.87 per share fell short of the $2.07 consensus estimate.
Axon Enterprise reported second-quarter revenue of $904 million, up 35% year-over-year, marking its tenth consecutive quarter of revenue growth above 30%. The company raised its full-year revenue growth outlook to 32%–34%, from a previous 30%–32%, while maintaining its adjusted EBITDA margin target of approximately 25.5%. Software and services revenue increased 36% to $398 million, with annual recurring revenue growing 39% to $1.6 billion. Net revenue retention reached 126%. Newer offerings including AI Era Plan, Records, Fusus and Axon 911 collectively grew roughly 70%, whilst the AI Era Plan alone grew nearly 700%. Axon's Dedrone business surpassed $100 million in quarterly revenue, contributing to a 123% increase in platform solutions revenue. The company noted potential opportunities in a $1.5 billion DHS counter-drone programme, though it hasn't estimated its likely share.
Axon reported Q2 2026 revenue of $904 million, up 35% year over year, marking its tenth consecutive quarter of growth exceeding 30%. The public safety technology company's annual recurring revenue grew 39% to $1.6 billion, with net revenue retention reaching 126%. Software and Services revenue increased 36% to $398 million, whilst Connected Devices revenue rose 35% to $507 million. Platform Solutions revenue surged 123% to $150 million, with Dedrone revenue surpassing $100 million. Future contracted bookings grew 41% year over year to $15.1 billion. Notable wins included two nine-figure agreements with major US cities and the largest individual TASER order in company history. Axon reported net income of $29 million and adjusted EBITDA of $242 million. The company raised its full-year revenue growth outlook to 32-34% whilst maintaining its adjusted EBITDA margin outlook at 25.5%.